Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial

Contemporary Clinical Trials

Volumn 33, Issue 1, 2012, Pages 184-196

  Visco, Anthony G ^a   Brubaker, Linda ^b   Richter, Holly E ^c   Nygaard, Ingrid ^d   Paraiso, Marie Fidela ^e   Menefee, Shawn A ^f   Schaffer, Joseph ^g   Wei, John ^h   Chai, Toby ⁱ   Janz, Nancy ^j   Spino, Cathie ^j   Meikle, Susan ^k  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f Kaiser Permanente San Diego ^*  (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF MARYLAND   (United States)

^j UNIVERSITY OF MICHIGAN   (United States)

^k EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

more..

Author keywords

Anticholinergic therapy; Botulinum toxin; Overactive bladder; Randomized clinical trial; Solifenacin; Trospium; Urge incontinence; Urgency urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; FESOTERODINE; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

ADULT; ARTICLE; BOTHERSOMENESS; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG MARKETING; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URGE INCONTINENCE; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; BOTULINUM TOXINS, TYPE A; CHOLINERGIC ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; NEUROMUSCULAR AGENTS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER; URINARY INCONTINENCE, URGE; URODYNAMICS; YOUNG ADULT;

EID: 84855341197     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2011.09.019     Document Type: Article

References (42)

1. Stewart W.F., Van Rooyen J.B., Cundiff G.W., et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003, 20:327-336.
2. Hartmann K.E., McPheeters M.L., Biller D.H., Ward R.M., McKoy J.N., Jerome J.N., et al. Treatment of Overactive Bladder in Women. Evid Rep Technol Assess (Summ) (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No 290-2007-10065-I) AHRQ Publication No 09-E017 Rockville, MD: Agency for Healthcare Research and Quality 2009, (187):1-8.
3. Diokno A.C., Sand P.K., Macdiarmid S., Shah R., Armstrong R.B. Perceptions and behaviours of women with bladder control problems. Fam Pract 2006, 23:568-577.
4. Schurch B., Stohrer M., Kramer G., Schmid D.M., Gaul G., Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000, 164:692-697.
5. Sahai A., Khan M.S., Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007, 177:2231-2236.
6. Brubaker L., Richter H.E., Visco A., Mahajan S., Nygaard I., Braun T.M., et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008, 180(1):217-222.
7. Werner M., Schmid D.M., Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 2005, 192:1735-1740.
8. Schmid D.M., Sauermann P., Werner M., et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006, 176:177-185.
9. Dmochowski R., Chapple C., Nitti V.W., Chancellor M., Everaert K., Thompson C., et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010, 184(6):2416-2422.
10. Wu J.M., Siddiqui N.Y., Amundsen C.L., Myers E.R., Havrilesky L.J., Visco A.G. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence. J Urol 2009, 181:2181-2186.
11. Burgio K.L., Kraus S.R., Menefee S., et al. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med 2008, 149:161-169.
12. Ciaschini P.M., Straus S.E., Dolovich L.R., et al. Community based intervention to optimize osteoporosis management: randomized controlled trial. BMC Geriatr 2010, 10:60.
13. Thompson B.T., Schoenfeld D. Usual care as the control group in clinical trials of nonpharmacologic interventions. Proc Am Thorac Soc 2007, 4:577-582.
14. Smelt A.F., van der Weele G.M., Blom J.W., Gussekloo J., Assendelft W.J. How usual is usual care in pragmatic intervention studies in primary care? An overview of recent trials. Br J Gen Pract 2010, 60:e305-e318.
15. Chapple C.R., Rechberger T., Al-Shukri S., et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004, 93:303-310.
16. Staskin D., Sand P., Zinner N., Dmochowski R. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol 2007, 178:978-983. (discussion 83-4).
17. Chancellor M.B., Zinner N., Whitmore K., et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther 2008, 30:1766-1781.
18. Cardozo L., Lisec M., Millard R., et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004, 172:1919-1924.
19. Zinner N., Gittelman M., Harris R., Susset J., Kanelos A., Auerbach S. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004, 171:2311-2315. (quiz 435).
20. Kelleher C., Cardozo L., Kobashi K., Lucente V. Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2006, 17:382-388.
21. Rudy D., Cline K., Harris R., Goldberg K., Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 2006, 67:275-280.
22. Nygaard I., Holcomb R. Reproducibility of the seven-day voiding diary in women with stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2000, 11:15-17.
23. Matza L.S., Thompson C.L., Krasnow J., Brewster-Jordan J., Zyczynski T., Coyne K.S. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn 2005, 24:215-225.
24. Coyne K.S., Matza L.S., Thompson C., Jumadilova Z., Bavendam T. The responsiveness of the OAB-q among OAB patient subgroups. Neurourol Urodyn 2007, 26:196-203.
25. Barber M.D., Walters M.D., Bump R.C. Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). Am J Obstet Gynecol 2005, 193:103-113.
26. Ware J., Kosinski M., Keller S.D. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34:220-233.
27. Rogers R.G., Coates K.W., Kammerer-Doak D., Khalsa S., Qualls C. A short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). Int Urogynecol J Pelvic Floor Dysfunct 2003, 14:164-168. (discussion 8).
28. Koopmanschap M.A. PRODISQ: a modular questionnaire on productivity and disease for economic evaluation studies. Expert Rev Pharmacoecon Outcomes Res 2005, 5:23-28.
29. Atkinson M.J., Kumar R., Cappelleri J.C., Hass S.L. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 2005, 8(Suppl. 1):S9-S24.
30. Yang Y., Brazier J., Tsuchiya A., Coyne K. Estimating a preference-based single index from the Overactive Bladder Questionnaire. Value Health 2009, 12:159-166.
31. Manca A., Hawkins N., Sculpher M.J. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005, 14:487-496.
32. Brazier J.E., Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004, 42:851-859.
33. Rubin D.B. Multiple imputation for nonresponse in surveys 1987, Wiley, New York.
34. Little R.J.A., Rubin D.B. Statistical analysis with missing data 1987, Wiley, New York.
35. Lan K.K., DeMets D.L. Discrete sequential boundaries for clinical trials. Biometrics 1983, 70:659-663.
36. Appell R.A. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997, 50:90-96. (discussion 7-9).
37. Gordon M.F., Barron R. Effectiveness of repeated treatment with botulinum toxin type A across different conditions. South Med J 2006, 99:853-861.
38. Karsenty G., Reitz A., Lindemann G., Boy S., Schurch B. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 2006, 68:1193-1197.
39. Borawski K.M., Foster R.T., Webster G.D., Amundsen C.L. Predicting implantation with a neuromodulator using two different test stimulation techniques: a prospective randomized study in urge incontinent women. Neurourol Urodyn 2007, 26:14-18.
40. Brubaker L., Kreder L., Richter H.E., Lavelle J., Wei J.T., Mahajan S., et al. Refractory urge urinary incontinence and botulinum a injection: the methods of the RUBI trial. J Appl Res 2006, 6(4):260-271.
41. Kuo H.C. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity?. Urology 2006, 68(5):993-997. (discussion 7-8).
42. Schmid D.M., Sauermann P., Werner M., Perucchini D., Sulser T., Schurch B. Experience including 5year results of 180 cases treated with low-dose (100U) botulinum-A toxin injections in the detrusor muscle for overactive bladder regractory to anticholinergics. Anaheim, CA: American Urological Association Annual Meeting. American Urological Association Annual Meeting 2007.